Company: HCWB
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-058961
Chunk: 42

Company: HCW Biologics Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 42
---
 of the total shares subject to the stock option grant will vest on September 8, 2025, subject to Dr. Rhode’s continuous service through the applicable vesting date. Note: Our named executive officers held the provided number of shares subject to outstanding stock options as of December 31, 2024 (pre-reverse stock split). On April 11, 2025, the Company effected a one-for-forty reverse stock split of its common stock. Our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 that are incorporated by reference into this proxy are presented without giving effect to the reverse stock split.

<div align='center'>29</div>

TABLE OF CONTENTS

EQUITY COMPENSATION PLAN INFORMATION We currently maintain the following equity compensation plans that provide for the issuance of shares of our common stock to our officers and other employees, directors and consultants, each of which has been approved by our stockholders: our 2021 Equity Incentive Plan, or the 2021 Plan, and our 2019 Equity Incentive Plan, or the 2019 Plan. The following table presents information as of December 31, 2024 with respect to compensation plans under which shares of our common stock may be issued.

| Plan Category                          | (a)                                                                                         
 Number of securities to be issued upon exercise of outstanding options, warrants and rights |           |     | (b)                                                                             
 Weighted-average exercise price of outstanding options, warrants and rights ($) |      |     | (c)                                                                                                                                         
 Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |           |
|:---------------------------------------|:--------------------------------------------------------------------------------------------|----------:|:----|:--------------------------------------------------------------------------------|-----:|:----|:--------------------------------------------------------------------------------------------------------------------------------------------|----------:|
| Equity compensation plans approved by  
 security holders (1)                   | 1,784,036(2)                                                                                |           |     | $                                                                               | 3.30 |     | 3,238,579(3)                                                                                                                                |           |
| Equity compensation plans not approved 
 by security holders                    | —                                                                                           |           |     | —                                                                               |      |     | —                                                                                                                                           |           |
| Total                                  |                                                                                             | 1,784,036 |     | $                                                                               | 3.30 |     |                                                                                                                                             | 3,238,579 |

(1) Includes the 2019